Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Sabina, Murgioni"'
Autor:
Antonella Galiano, Alessandra Feltrin, Ardi Pambuku, Leda Lo Mauro, Chiara De Toni, Sabina Murgioni, Caterina Soldà, Marco Maruzzo, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Veneto Institute of Oncology has activated a simultaneous care outpatient clinic (SCOC) in which cancer patients with advanced‐stage cancer are evaluated by oncologist and palliative care specialists. This cross‐sectional stud
Externí odkaz:
https://doaj.org/article/d1d125f1a4c5498d8c05e577abb3f4a2
Autor:
Matteo Scopel, Eugenio De Carlo, Francesca Bergamo, Sabina Murgioni, Riccardo Carandina, Anna Rita Cervino, Marta Burei, Federica Vianello, Vittorina Zagonel, Matteo Fassan, Roberto Vettor
Publikováno v:
Endocrine Connections, Vol 11, Iss 7, Pp 1-9 (2022)
We considered 351 patients affected by neuroendocrine tumors (NETs), followed at the University Hospital of Padua and at the Veneto Oncological Institute. Of these, 72 (20.5%) suffered from bone metastases. The sample was divided according to the tim
Externí odkaz:
https://doaj.org/article/76dacecd3fc948f191fcf765cd4d291b
Autor:
Antonella Galiano, Stefania Schiavon, Mariateresa Nardi, Irene Guglieri, Ardi Pambuku, Rosalba Martino, Maital Bolshinsky, Sabina Murgioni, Rossana Intini, Caterina Soldà, Dario Marino, Francesca Daniel, Chiara De Toni, Chiara Pittarello, Benedetta Chiusole, Alessandra Anna Prete, Davide Bimbatti, Floriana Nappo, Mario Caccese, Francesca Bergamo, Antonella Brunello, Sara Lonardi, Vittorina Zagonel
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundEarly activation of palliative care for patients with advanced cancer is central in the treatment trajectory. At the Veneto Institute of Oncology, a simultaneous-care outpatient clinic (SCOC) has been active since 2014, where patients are e
Externí odkaz:
https://doaj.org/article/1f0ca2d93e7d4431883b0b66bbe200d0
Autor:
Fotios Loupakis, Giulia Maddalena, Ilaria Depetris, Sabina Murgioni, Francesca Bergamo, Angelo Paolo Dei Tos, Massimo Rugge, Giada Munari, Andrew Nguyen, Christopher Szeto, Vittorina Zagonel, Sara Lonardi, Matteo Fassan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune
Externí odkaz:
https://doaj.org/article/42bd19ba238948ee815a95ee2bf81be2
Autor:
Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, Mirella Giordano, Aurélie Catteau, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Kimberly McGregor, Francesca Bergamo, Veronica Conca, Simone Leonetti, Federica Morano, Giorgio Papiani, Emiliano Tamburini, Maria Bensi, Sabina Murgioni, Douglas Teller Ross, Alessandro Passardi, Isabelle Boquet, Tyler J. Nielsen, Jérôme Galon, Matthew Gordon Varga, Brock L. Schweitzer, Chiara Cremolini
Publikováno v:
Clinical Cancer Research. :OF1-OF8
Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc7a8416e2540ffff3da6a3eefd68d91
https://doi.org/10.1158/1078-0432.ccr-22-3878
https://doi.org/10.1158/1078-0432.ccr-22-3878
Autor:
Vittoria Matilde, Piva, Maria Caterina, De Grandis, Irene Sole, Zuin, Valentina, Angerilli, Floriana, Nappo, Rita, Alfieri, Selma, Ahcene Djaballah, Sabina, Murgioni, Francesca, Bergamo, Matteo, Fassan, Michele, Valmasoni, Sara, Lonardi
Publikováno v:
Updates in Surgery. 75:305-312
Gastroesophageal adenocarcinoma is a challenging disease due to its poor prognosis and the presence of few therapeutic options. For these reasons, it is mandatory to identify the subgroup of patients who are at high risk for relapse after curative-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c338684bb4701aa3782fce5787d9db
https://doi.org/10.1007/s13304-022-01379-2
https://doi.org/10.1007/s13304-022-01379-2
Autor:
Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo, Federica Marmorino, Francesca Bergamo, Emiliano Tamburini, Alessandro Passardi, Giovanni Randon, Sabina Murgioni, Beatrice Borelli, Angela Buonadonna, Mirella Giordano, Gabriella Fontanini, Veronica Conca, Vincenzo Formica, Massimo Aglietta, Roberto Bordonaro, Giuseppe Aprile, Gianluca Masi, Luca Boni, Chiara Cremolini
Publikováno v:
Journal of Clinical Oncology. 40:2878-2888
PURPOSE To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activity of fluorouracil, leucovorin, and oxalipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97dd4b721033a3bd65c69f96efc91294
https://doi.org/10.1200/jco.22.00839
https://doi.org/10.1200/jco.22.00839
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFOXIRI pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4332a88187297585a34006d3116e37fa
https://doi.org/10.1158/1078-0432.22692642
https://doi.org/10.1158/1078-0432.22692642
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Purpose:AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c77aca2057d946a319565137c40acb
https://doi.org/10.1158/1078-0432.c.6615933.v1
https://doi.org/10.1158/1078-0432.c.6615933.v1
Autor:
Chiara Cremolini, Brock L. Schweitzer, Matthew Gordon Varga, Jérôme Galon, Tyler J. Nielsen, Isabelle Boquet, Alessandro Passardi, Douglas Teller Ross, Sabina Murgioni, Maria Bensi, Emiliano Tamburini, Giorgio Papiani, Federica Morano, Simone Leonetti, Veronica Conca, Francesca Bergamo, Kimberly McGregor, Lisa Salvatore, Filippo Pietrantonio, Daniele Rossini, Aurélie Catteau, Mirella Giordano, Robert Seitz, Alessandra Boccaccino, Carlotta Antoniotti
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50452b50c4a7164dbe128538020db82a
https://doi.org/10.1158/1078-0432.22692633
https://doi.org/10.1158/1078-0432.22692633